EMERYVILLE, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced that it will webcast a teleconference with management to discuss third quarter 2008 financial results and provide a general business overview on Thursday, November 06, 2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the third quarter ended September 30, 2008 will be released earlier that day.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.
Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.
CONTACT: Alex Santos of Onyx Pharmaceuticals, Inc., +1-510-597-6504
Web site: http://www.onyx-pharm.com/
